There is one clinical trial.

Clinical Trials

1 Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19

The disease caused by the new coronavirus, SARS-CoV-2, called COVID-19, it has considered a worldwide pandemia by the WHO. Suddently, it produces a lot of patients severe ill, in a little geographic area, that could surpase the resourses of the any health system in the world. There is no documentation of an effective alternative for the treatment of the severe ill patients, that can reduce the mortality or the adverse events suffered by these people. It is has suggested the usefulness of the Mesenchymal Stem cells (MSC) for the management of these patients, thanks to their direct and indirect antiviral capacity, and its potency as immunomodulator, that could ameliorate the lung disease and the severity of COVID-19.

NCT04429763 COVID-19 Biological: Umbilical cord derived mesenchymal stem cells Biological: Placebo

No related HPO nodes (Using clinical trials)